金河生物科技股份有限公司2026年第二次临时股东会决议的公告

Core Viewpoint - The company held its second extraordinary general meeting of shareholders in 2026, where several key proposals were approved without any objections from shareholders [1][2]. Group 1: Meeting Details - The notice for the extraordinary general meeting was published on January 31, 2026, in various financial newspapers and on the official website [3]. - The meeting took place on February 27, 2026, at 14:30, with both on-site and online voting options available [4]. - The record date for shareholders to participate was set for February 12, 2026, and the meeting was held at the company's conference room in Inner Mongolia [5]. Group 2: Attendance and Voting - A total of 440 shareholders and their authorized representatives attended the meeting, representing 247,285,941 shares, which is 32.6315% of the total voting shares [6]. - Among the attendees, 11 participated in person, holding 240,783,611 shares (31.7735%), while 429 participated online, holding 6,502,330 shares (0.8580%) [6]. - The meeting included participation from some directors, senior management, and a witnessing lawyer from Beijing Hualian Law Firm [7]. Group 3: Resolutions Passed - The following proposals were approved during the meeting: 1. Proposal for the provision of goodwill impairment [8]. 2. Proposal for the subsidiary to engage in sale-leaseback financing and provide guarantees [8]. 3. Proposal to change the use of raised funds [8]. Group 4: Legal Opinions - The legal opinions provided by Beijing Hualian Law Firm confirmed that the meeting's procedures complied with relevant laws and regulations, and the voting results were deemed legal and valid [8]. Group 5: Documentation - The resolutions from the extraordinary general meeting and the legal opinion from the law firm are available for review [9].